These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28524118)

  • 1. Novel Radiolabeled Bisphosphonates for PET Diagnosis and Endoradiotherapy of Bone Metastases.
    Pfannkuchen N; Meckel M; Bergmann R; Bachmann M; Bal C; Sathekge M; Mohnike W; Baum RP; Rösch F
    Pharmaceuticals (Basel); 2017 May; 10(2):. PubMed ID: 28524118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid.
    Meckel M; Bergmann R; Miederer M; Roesch F
    EJNMMI Radiopharm Chem; 2017; 1(1):14. PubMed ID: 29564390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (68)Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitter.
    Fellner M; Biesalski B; Bausbacher N; Kubícek V; Hermann P; Rösch F; Thews O
    Nucl Med Biol; 2012 Oct; 39(7):993-9. PubMed ID: 22633217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A DOTA based bisphosphonate with an albumin binding moiety for delayed body clearance for bone targeting.
    Meckel M; Kubíček V; Hermann P; Miederer M; Rösch F
    Nucl Med Biol; 2016 Nov; 43(11):670-678. PubMed ID: 27560354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and evaluation of a novel 68Ga-chelate-conjugated bisphosphonate as a bone-seeking agent for PET imaging.
    Suzuki K; Satake M; Suwada J; Oshikiri S; Ashino H; Dozono H; Hino A; Kasahara H; Minamizawa T
    Nucl Med Biol; 2011 Oct; 38(7):1011-8. PubMed ID: 21982572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo comparison of DOTA based 68Ga-labelled bisphosphonates for bone imaging in non-tumour models.
    Meckel M; Fellner M; Thieme N; Bergmann R; Kubicek V; Rösch F
    Nucl Med Biol; 2013 Aug; 40(6):823-30. PubMed ID: 23915801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (177)Lu-labelled macrocyclic bisphosphonates for targeting bone metastasis in cancer treatment.
    Bergmann R; Meckel M; Kubíček V; Pietzsch J; Steinbach J; Hermann P; Rösch F
    EJNMMI Res; 2016 Dec; 6(1):5. PubMed ID: 26780082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
    Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
    J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New (68)Ga-PhenA bisphosphonates as potential bone imaging agents.
    Wu Z; Zha Z; Choi SR; Plössl K; Zhu L; Kung HF
    Nucl Med Biol; 2016 Jun; 43(6):360-71. PubMed ID: 27260777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Samarium-153-(4-[((bis (phosphonomethyl)) carbamoyl) methyl]-7,10-bis (carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl) acetic acid: A novel agent for bone pain palliation therapy.
    Yousefnia H; Enayati R; Hosntalab M; Zolghadri S; Bahrami-Samani A
    J Cancer Res Ther; 2016; 12(3):1117-1123. PubMed ID: 28054521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
    Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
    Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of hybrid
    Janssen JC; Meißner S; Woythal N; Prasad V; Brenner W; Diederichs G; Hamm B; Makowski MR
    Eur Radiol; 2018 Feb; 28(2):610-619. PubMed ID: 28779400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detailed evaluation on the effect of metal ion impurities on complexation of generator eluted 68Ga with different bifunctional chelators.
    Chakravarty R; Chakraborty S; Dash A; Pillai MR
    Nucl Med Biol; 2013 Feb; 40(2):197-205. PubMed ID: 23218795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a New Folate-Derived Ga-68-Based PET Imaging Agent.
    Brand C; Longo VA; Groaning M; Weber WA; Reiner T
    Mol Imaging Biol; 2017 Oct; 19(5):754-761. PubMed ID: 28194631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of a novel, versatile bifunctional chelator on theranostic properties of a minigastrin analogue.
    Pfister J; Summer D; Rangger C; Petrik M; von Guggenberg E; Minazzi P; Giovenzana GB; Aloj L; Decristoforo C
    EJNMMI Res; 2015 Dec; 5(1):74. PubMed ID: 26669693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical evaluation of 68Ga-labeled 1,4,7-triazacyclononane-1,4,7-triacetic acid-ubiquicidin as a radioligand for PET infection imaging.
    Ebenhan T; Zeevaart JR; Venter JD; Govender T; Kruger GH; Jarvis NV; Sathekge MM
    J Nucl Med; 2014 Feb; 55(2):308-14. PubMed ID: 24434293
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Pfannkuchen N; Bausbacher N; Pektor S; Miederer M; Rosch F
    Curr Radiopharm; 2018; 11(3):223-230. PubMed ID: 29866026
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.